Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alyssa M Peckham

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
BMJ (Clinical Research Ed.)|December 1, 2018
Need for international classification of gabapentin as a controlled substanceAlyssa M Peckham, David A Sclar
Federal Practitioner : for the Health Care Professionals of the VA, Dod, and PHS|February 16, 2019
The Overdose Education and Naloxone Distribution Program at a VA HospitalAlyssa M Peckham, Douglas L Boggs
Journal of Pharmacy Practice|February 20, 2018
VMAT2 Inhibitors for Tardive Dyskinesia-Practice ImplicationsAlyssa M Peckham, Jessica A Nicewonder
The Primary Care Companion for CNS Disorders|March 22, 2019
Quantifying Gabapentin Misuse With OpioidsAlyssa M Peckham, David A Sclar
Open Forum Infectious Diseases|November 26, 2020
Opportunities to Offer Harm Reduction to People who Inject Drugs During Infectious Disease Encounters: Narrative ReviewAlyssa M Peckham, Erika H Young
Annals of Internal Medicine|June 18, 2019
Combined Gabapentinoid and Opioid UseAlyssa M Peckham, David A Sclar
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|December 24, 2021
State-level response to gabapentin misuse in the United States: Implications and future directionZoe A Karavolis, Andrew B Su, Alyssa M Peckham
Risk Management and Healthcare Policy|August 30, 2018
Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilanceAlyssa M Peckham, Maria J Ananickal, David A Sclar
Pain and Therapy|February 10, 2021
Letter to the Editor: Comment on "Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth"Alyssa M Peckham, Jordan R Covvey, Kirk E Evoy
BMJ (Clinical Research Ed.)|December 2, 2017
Call for increased pharmacovigilance of gabapentinAlyssa M Peckham, Kathleen A Fairman, David A Sclar
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
BMJ (Clinical Research Ed.)|December 1, 2018
Need for international classification of gabapentin as a controlled substanceAlyssa M Peckham, David A Sclar
Federal Practitioner : for the Health Care Professionals of the VA, Dod, and PHS|February 16, 2019
The Overdose Education and Naloxone Distribution Program at a VA HospitalAlyssa M Peckham, Douglas L Boggs
Journal of Pharmacy Practice|February 20, 2018
VMAT2 Inhibitors for Tardive Dyskinesia-Practice ImplicationsAlyssa M Peckham, Jessica A Nicewonder
The Primary Care Companion for CNS Disorders|March 22, 2019
Quantifying Gabapentin Misuse With OpioidsAlyssa M Peckham, David A Sclar
Open Forum Infectious Diseases|November 26, 2020
Opportunities to Offer Harm Reduction to People who Inject Drugs During Infectious Disease Encounters: Narrative ReviewAlyssa M Peckham, Erika H Young
Annals of Internal Medicine|June 18, 2019
Combined Gabapentinoid and Opioid UseAlyssa M Peckham, David A Sclar
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|December 24, 2021
State-level response to gabapentin misuse in the United States: Implications and future directionZoe A Karavolis, Andrew B Su, Alyssa M Peckham
Risk Management and Healthcare Policy|August 30, 2018
Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilanceAlyssa M Peckham, Maria J Ananickal, David A Sclar
Pain and Therapy|February 10, 2021
Letter to the Editor: Comment on "Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth"Alyssa M Peckham, Jordan R Covvey, Kirk E Evoy
BMJ (Clinical Research Ed.)|December 2, 2017
Call for increased pharmacovigilance of gabapentinAlyssa M Peckham, Kathleen A Fairman, David A Sclar
Pageof 5